Axis-Shield agrees £235m sale to Alere
The medical diagnostics firm Axis-Shield has agreed to be bought by its larger peer, Alere, after the US group ended a three-month battle by increasing its offer to £235m.
Axis-Shield shares rose 4 per cent to 468p, below the 470p per share level of the new bid. Its Afinion system competes with Alere's Cholestech LDX machine, which measures cholesterol levels.
Axis-Shield rejected Alere's bid of £230m in July. Alere then took the 460p offer directly to Axis-Shield's shareholders, and last week raised its stake in the firm to 30 per cent.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies